MipSalus receives a grant to develop a breakthrough treatment of PKU

February 2014: Højteknologifonden (now: Innovation Fund Denmark) has selected MipSalus for a DKK 13 million grant. With the grant, MipSalus will continue the development of the company’s breakthrough treatment for the orphan disease Phenylketonuria (PKU) in close collaboration with Aarhus University, Denmark.